Implications of cancer evolution for drug development

被引：0
|
作者：
Samra Turajlic
Charles Swanton
机构：
[1] Translational Cancer Therapeutics Laboratory,
[2] The Francis Crick Institute,undefined
[3] Renal and Skin Units,undefined
[4] The Royal Marsden Hospital,undefined
[5] Cancer Research UK Lung Cancer Centre of Excellence,undefined
[6] University College London Cancer Institute,undefined
来源：
Nature Reviews Drug Discovery | 2017年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Tumour evolution, which results in the existence of multiple distinct populations of cancer cells within the same tumour and the same patient, is increasingly appreciated to have a key role in drug resistance. In this article, we discuss the implications for drug development, including approaches to reduce the likelihood of the emergence of drug resistance.
引用
收藏
页码：441 / 442
页数：1
相关论文
共 50 条
  • [21] LEUKOTRIENES IN DISEASE IMPLICATIONS FOR DRUG DEVELOPMENT
    HIGGS, GA
    MONCADA, S
    DRUGS, 1985, 30 (01) : 1 - 5
  • [22] Ethnic diversity: Implications for drug development
    Gross, Annette S.
    DRUG METABOLISM REVIEWS, 2006, 38 : 30 - 31
  • [23] CAST - IMPLICATIONS FOR DRUG DEVELOPMENT - COMMENTARY
    WOOSLEY, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (05) : 553 - 556
  • [24] EVOLUTION OF THEORETICAL METHODS IN DRUG DEVELOPMENT
    HANSCH, C
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1986, 192 : 19 - HIST
  • [25] The evolution of antiepileptic drug development and regulation
    Arzimanoglou, Alexis
    Ben-Menachem, Elinor
    Cramer, Joyce
    Glauser, Tracy
    Seeruthun, Rav
    Harrison, Miranda
    EPILEPTIC DISORDERS, 2010, 12 (01) : 3 - 15
  • [26] THE NEWEST STAGE IN THE EVOLUTION OF DRUG DEVELOPMENT
    Ross, Jeffrey S.
    DRUG NEWS & PERSPECTIVES, 2009, 22 (01) : 59 - 59
  • [27] Evolution and intelligent design in drug development
    Agafonov, Roman V.
    Wilson, Christopher
    Kern, Dorothee
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2015, 2
  • [28] In vitro evolution of proteins for drug development
    Delagrave, S
    Murphy, DJ
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2003, 1 (01) : 187 - 198
  • [29] DEREGULATION OF THE AKT-RELATED PATHWAY IN CANCER: IMPLICATIONS FOR RESISTANCE TO THERAPY AND DRUG DEVELOPMENT
    Romano, G.
    DRUGS OF THE FUTURE, 2013, 38 (01) : 37 - 42
  • [30] Roles of PPAR activation in cancer therapeutic resistance: Implications for combination therapy and drug development
    Zhang, Yanxia
    Xiao, Bin
    Liu, Yunduo
    Wu, Shunhong
    Xiang, Qin
    Xiao, Yuhan
    Zhao, Junxiu
    Yuan, Ruanfei
    Xie, Keping
    Li, Linhai
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 964
12345